Pharmacovigilance programme of India

被引：13
|
作者：
Vivekanandan, Kalaiselvan [1 ]
Prakash, Jai [1 ]
Singh, Gyanendra Nath [1 ]
机构：
[1] Indian Pharmacopoeia Commiss, Sect 23, Ghaziabad 201002, Uttar Pradesh, India
来源：
ARCHIVES OF PHARMACY PRACTICE | 2012年 / 3卷 / 03期
关键词：
Pharmacovigilance; ADRs; VigiFlow; Indian Pharmacopoeia Commission; Central Drugs Standard Control Organization;
D O I：
10.4103/2045-080X.116605
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The monitoring and reporting of adverse drug reactions (ADRs) through pharmacovigilance is vital to patient safety and rational prescribing. In India, Central Drugs Standard Control Organization (CDSCO) initiated Pharmacovigilance Programme of India (PvPI) to report ADRs through ADRs monitoring centres in India. Indian Pharmacopoeia Commission (IPC) is functioning as National Coordination Centre (NCC) for PvPI. The ADRs are reported to NCC through VigiFlow by various centres are evaluated and committed to Uppsala Monitoring Centre, Sweden. The potential benefit of the PvPI is aimed to reducing or eliminating a harm of medicine. Continuous efforts of the healthcare professionals and the patients are expected to make this as one of the most successful and effective programmes. The present article updates the status and future plan of PvPI.
引用
收藏
页码：229 / 232
页数：4
相关论文
共 50 条
  • [1] An update on the Pharmacovigilance Programme of India
    Lihite, Ratan J.
    Lahkar, Mangala
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [2] Pharmacovigilance Programme of India: Recent developments and future perspectives
    Kalaiselvan, Vivekanandan
    Thota, Prasad
    Singh, Gyanendra Nath
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2016, 48 (06) : 624 - 628
  • [3] Targeted spontaneous reporting on drug safety alerts issued by pharmacovigilance programme of India: A new origin of pharmacovigilance in India
    Thota, Prasad
    Sidhu, Shabir
    Medhi, Bikash
    Sarma, Phulen
    Prakash, Ajay
    Vivekanandan, Kalaiselvan
    Thota, Anusha
    [J]. JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2019, 10 (01) : 33 - 34
  • [4] Statistical Signal Process in R Language in the Pharmacovigilance Programme of India
    Aman Kumar
    Jitin Ahuja
    Tarani Prakash Shrivastava
    Vipin Kumar
    Vivekanandan Kalaiselvan
    [J]. Therapeutic Innovation & Regulatory Science, 2018, 52 : 329 - 333
  • [5] Statistical Signal Process in R Language in the Pharmacovigilance Programme of India
    Kumar, Aman
    Ahuja, Jitin
    Shrivastava, Tarani Prakash
    Kumar, Vipin
    Kalaiselvan, Vivekanandan
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (03) : 329 - 333
  • [6] Adverse drug reactions reporting culture in Pharmacovigilance Programme of India
    Kalaiselvan, Vivekanandan
    Prasad, Thota
    Bisht, Akanksha
    Singh, Surinder
    Singh, Gyanendra Nath
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2014, 140 : 563 - 564
  • [7] Pharmacovigilante's in the Pharmacovigilance Programme of India: Ideal Qualities and Skills
    Vivekanandan, Kalaiselvan
    Thota, Prasad
    Janarthanan, Vijay Venkatraman
    Singh, Gyanendra Nath
    [J]. JOURNAL OF YOUNG PHARMACISTS, 2016, 8 (03) : 291 - +
  • [8] Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India
    Prakash, Jai
    Sachdeva, Raghav
    Shrivastava, Tarani Prakash
    Jayachandran, C. V.
    Sahu, Aseem
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2021, 53 (02) : 143 - 152
  • [9] Integrating Pharmacovigilance in Revised National Tuberculosis Control Programme of India: A Pilot Study
    Parthasarathi, G.
    Niveditha, H.
    Harugeri, A.
    Ramesh, M.
    [J]. DRUG SAFETY, 2010, 33 (10) : 915 - 916
  • [10] Spontaneous Reporting of Adverse Events Due to Herbal Products in Pharmacovigilance Programme of India
    Kalaiselvan, V.
    Thota, P.
    Saurabh, A.
    Kumar, R.
    Singh, A.
    [J]. DRUG SAFETY, 2014, 37 (10) : 840 - 840
12345